BRPI0509606A - emulsões de óleo-em-água microfluidizadas e composições para vacinas - Google Patents
emulsões de óleo-em-água microfluidizadas e composições para vacinasInfo
- Publication number
- BRPI0509606A BRPI0509606A BRPI0509606-5A BRPI0509606A BRPI0509606A BR PI0509606 A BRPI0509606 A BR PI0509606A BR PI0509606 A BRPI0509606 A BR PI0509606A BR PI0509606 A BRPI0509606 A BR PI0509606A
- Authority
- BR
- Brazil
- Prior art keywords
- water emulsions
- vaccine compositions
- emulsions
- present
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"EMULSõES DE óLEO-EM-áGUA MICROFLUIDIZADAS E COMPOSIçõES PARA VACINAS". A presente invenção refere-se emulsões de óleo-em-água em submícron úteis como um adjuvante para vacina para aumentar a imunogenicidade de antígenos. A presente invenção fornece ainda composições para vacina contendo um antígeno combinado com tais emulsões intrínseca ou extrinsecamente. São também fornecidos pela presente invenção processos de preparação das emulsões e vacinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55967704P | 2004-04-05 | 2004-04-05 | |
PCT/IB2005/000804 WO2005097181A1 (en) | 2004-04-05 | 2005-03-24 | Microfluidized oil-in-water emulsions and vaccine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0509606A true BRPI0509606A (pt) | 2007-09-18 |
BRPI0509606B1 BRPI0509606B1 (pt) | 2019-01-15 |
Family
ID=34961993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509606A BRPI0509606B1 (pt) | 2004-04-05 | 2005-03-24 | emulsões de óleo-em-água microfluidizadas e composições para vacinas |
Country Status (23)
Country | Link |
---|---|
US (1) | US7122191B2 (pt) |
EP (2) | EP1742659B1 (pt) |
JP (2) | JP5393978B2 (pt) |
KR (5) | KR20090051129A (pt) |
CN (1) | CN1997390B (pt) |
AR (1) | AR048822A1 (pt) |
AU (1) | AU2005230708B2 (pt) |
BR (1) | BRPI0509606B1 (pt) |
CA (1) | CA2561914C (pt) |
DK (1) | DK1742659T3 (pt) |
ES (1) | ES2409782T3 (pt) |
HK (1) | HK1108830A1 (pt) |
NO (1) | NO341034B1 (pt) |
NZ (1) | NZ550152A (pt) |
PL (1) | PL1742659T3 (pt) |
PT (1) | PT1742659E (pt) |
RU (1) | RU2347586C2 (pt) |
SI (1) | SI1742659T1 (pt) |
TW (1) | TWI301067B (pt) |
UA (1) | UA89631C2 (pt) |
UY (1) | UY28840A1 (pt) |
WO (1) | WO2005097181A1 (pt) |
ZA (1) | ZA200608200B (pt) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39494E1 (en) * | 1992-02-27 | 2007-02-27 | Intervet Inc. | Inactivated mycoplasma hyopneumoniae and uses therefor |
AU1486102A (en) | 2000-11-07 | 2002-05-21 | Immunovaccine Technologies Inc | Vaccines with enhanced immune response and methods for their preparation |
AR044732A1 (es) * | 2002-11-08 | 2005-10-05 | H P B S A | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
SI1742659T1 (sl) * | 2004-04-05 | 2013-07-31 | Zoetis P Llc | Mikrofluidizirane emulzije olja v vodi in sestavki cepiv |
EP1896062B1 (en) | 2005-06-27 | 2010-03-31 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
AU2006279323B2 (en) * | 2005-08-16 | 2013-08-01 | Merck Sharp & Dohme Corp. | Influenza recombinant subunit vaccine |
DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
JP2009514850A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
US20090220541A1 (en) | 2005-11-04 | 2009-09-03 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines |
NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
EP1792619A1 (en) * | 2005-11-28 | 2007-06-06 | Laboratorios Maymo, S.A. | Beta-sitosterol for treating porcine respiratory disease complex |
EP2478916B1 (en) | 2006-01-27 | 2020-04-01 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
US20100226932A1 (en) * | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
WO2007126825A2 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
AU2007297178B2 (en) | 2006-09-11 | 2014-07-24 | Novartis Ag | Making influenza virus vaccines without using eggs |
CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
NZ582595A (en) | 2007-06-27 | 2012-07-27 | Novartis Ag | Low-additive influenza vaccines |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
BRPI0818545A2 (pt) | 2007-10-19 | 2017-07-04 | Novartis Ag | formulações de vacinais meningocócicas |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
AU2009227674C1 (en) | 2008-03-18 | 2015-01-29 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
ES2712505T3 (es) | 2008-04-17 | 2019-05-13 | Pds Biotechnology Corp | Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos |
TWI551295B (zh) | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | 防備胞內勞森菌(Lawsonia intracellularis)用疫苗 |
EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
RU2510280C2 (ru) * | 2008-06-27 | 2014-03-27 | Пфайзер Инк. | Новые адъювантные композиции |
AU2012258478B2 (en) * | 2008-06-27 | 2013-10-03 | Zoetis Services Llc | Novel adjuvant compositions |
AU2009294318B2 (en) | 2008-09-18 | 2014-04-24 | Novartis Ag | Vaccine adjuvant combinations |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
EP2396031A1 (en) | 2009-02-10 | 2011-12-21 | Novartis AG | Influenza vaccines with increased amounts of h3 antigen |
AU2010220103A1 (en) | 2009-03-06 | 2011-09-22 | Novartis Ag | Chlamydia antigens |
EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
SI2401384T1 (sl) | 2009-05-21 | 2013-01-31 | Novartis Ag | Reverzna genetika z uporabo neendogenih pol i promotorjev |
CN103764160A (zh) | 2009-05-29 | 2014-04-30 | 诺华有限公司 | 流感病毒血凝素试验 |
CN102666571A (zh) | 2009-07-07 | 2012-09-12 | 诺华有限公司 | 保守的大肠杆菌免疫原 |
SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
EP2837386B1 (en) | 2009-07-16 | 2018-03-07 | GlaxoSmithKline Biologicals SA | Detoxified Escherichia coli immunogens |
WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
JP5911799B2 (ja) * | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
AU2010293902A1 (en) | 2009-09-10 | 2012-03-22 | Novartis Ag | Combination vaccines against respiratory tract diseases |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
CA2776004A1 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
CA2778332A1 (en) | 2009-10-20 | 2011-04-28 | Novartis Ag | Improved reverse genetics methods for virus rescue |
US20120219605A1 (en) * | 2009-11-05 | 2012-08-30 | Peter Blackburn | Adjuvanted nanoparticulate influenza vaccine |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
EA025622B1 (ru) | 2009-12-03 | 2017-01-30 | Новартис Аг | Способ получения содержащей сквален эмульсии масла |
DE102009056871A1 (de) * | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
DE102009056883B4 (de) * | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
PL2356983T3 (pl) * | 2009-12-03 | 2013-08-30 | Novartis Ag | Cyrkulacja komponentów w czasie homogenizacji emulsji |
EP2519265B1 (en) | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | Polysaccharide immunogens conjugated to e. coli carrier proteins |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
CN101926994B (zh) * | 2010-08-19 | 2012-10-10 | 中国医学科学院医学生物学研究所 | 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗 |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
HUE043879T2 (hu) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | RSV-immunizálási rend |
CA2828844C (en) | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
US20140248314A1 (en) | 2011-05-13 | 2014-09-04 | Novartis Ag | Pre-fusion rsv f antigens |
WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
TR201909110T4 (tr) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler. |
SG11201401177WA (en) | 2011-10-06 | 2014-04-28 | Immunovaccine Technologies Inc | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
AU2012324398A1 (en) | 2011-10-20 | 2014-05-01 | Seqirus UK Limited | Adjuvanted influenza B virus vaccines for pediatric priming |
EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
JP2016539314A (ja) | 2011-12-12 | 2016-12-15 | ノバルティス アーゲー | インフルエンザウイルス血球凝集素のためのアッセイ法 |
EP2793939A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Stable compositions for immunising against staphylococcus aureus |
JP6054883B2 (ja) | 2012-03-02 | 2016-12-27 | ノバルティス アーゲー | インフルエンザウイルスの再集合 |
WO2013132041A2 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
US20150161359A1 (en) | 2012-06-04 | 2015-06-11 | Novartis Ag | Methods for safety testing |
TR201910573T4 (tr) | 2012-08-31 | 2019-08-21 | Glaxosmithkline Biologicals Sa | Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler. |
US20150203543A1 (en) | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
MX2015002717A (es) | 2012-09-06 | 2015-05-15 | Novartis Ag | Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina. |
CA2882382A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
JP2015530413A (ja) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | 改良されたワクチン組成物および使用方法 |
US20160101187A1 (en) | 2012-10-02 | 2016-04-14 | Novartis Ag | Nonlinear saccharide conjugates |
ES2717441T3 (es) | 2012-10-09 | 2019-06-21 | Univ Gent | Vacuna contra Cooperia |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
SG11201502599TA (en) | 2012-10-12 | 2015-05-28 | Glaxosmithkline Biolog Sa | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
RU2018137673A (ru) | 2012-11-30 | 2019-03-22 | Глаксосмитклайн Байолоджикалс Са | Антигены и комбинации антигенов pseudomonas |
AU2013354219A1 (en) | 2012-12-03 | 2015-07-02 | Novartis Ag | Reassortant influenza a viren |
UY34506A (es) | 2012-12-10 | 2014-06-30 | Fernando Amaury Ferreira Chiesa | Adyuvante de vacunación, preparación y vacunas que lo contienen |
JP2016502994A (ja) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ジフテリア及び/又は破傷風から防御するためのコンジュゲート |
CA2905612A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
CN105828835A (zh) | 2013-05-10 | 2016-08-03 | 诺华股份有限公司 | 避免流感疫苗中的发作性嗜睡病风险 |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
CN105722976A (zh) | 2013-06-06 | 2016-06-29 | 诺华股份有限公司 | 流感病毒重配 |
EP3049105B1 (en) | 2013-09-19 | 2020-12-30 | Moredun Research Institute | Vaccine |
RU2016114713A (ru) | 2013-10-17 | 2017-11-20 | Зоэтис Сервисиз Ллс | Способы и композиции для лечения s. equi инфекции |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
WO2015080959A1 (en) * | 2013-11-26 | 2015-06-04 | Zoetis Llc | Compositions for induction of immune response |
US10280199B2 (en) | 2014-02-07 | 2019-05-07 | Phibro Animal Health Corporation | Coronavirus proteins and antigens |
SG11201606887WA (en) | 2014-03-26 | 2016-09-29 | Glaxosmithkline Biolog Sa | Mutant staphylococcal antigens |
CN104013955B (zh) * | 2014-06-18 | 2016-02-24 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
MX2017009306A (es) * | 2015-01-16 | 2017-11-08 | Zoetis Services Llc | Vacuna contra la fiebre aftosa. |
WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US20190105385A1 (en) * | 2016-03-23 | 2019-04-11 | Intervet Inc. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
WO2017196979A1 (en) * | 2016-05-10 | 2017-11-16 | The Regents Of The University Of Michigan | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration |
US10279031B2 (en) | 2016-05-11 | 2019-05-07 | Phibro Animal Health Corporation | Composition comprising antigens and a mucosal adjuvant and a method for using |
WO2017196318A1 (en) * | 2016-05-11 | 2017-11-16 | Phibro Animal Health Corporation | A composition comprising antigens and a mucosal adjuvant and a method for using |
WO2020055503A1 (en) | 2018-09-14 | 2020-03-19 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
US11419932B2 (en) | 2019-01-24 | 2022-08-23 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
CN115380107A (zh) | 2019-11-18 | 2022-11-22 | 思齐乐私人有限公司 | 用于产生重配流感病毒的方法 |
TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
US20230190920A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
WO2023154960A1 (en) | 2022-02-14 | 2023-08-17 | University Of Georgia Research Foundation, Inc. | Pan-pneumovirus vaccine compositions and methods of use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310550A (en) | 1979-10-26 | 1982-01-12 | Pfizer Inc. | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
US4908154A (en) | 1981-04-17 | 1990-03-13 | Biotechnology Development Corporation | Method of forming a microemulsion |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5690942A (en) | 1995-06-02 | 1997-11-25 | American Home Products Corporation | Adjuvants for viral vaccines |
US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DE69838992T2 (de) * | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
ATE286511T1 (de) * | 1999-02-17 | 2005-01-15 | Pfizer Prod Inc | Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren |
EP2322210A1 (en) * | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
DE10106446A1 (de) * | 2001-02-09 | 2002-10-10 | Haarmann & Reimer Gmbh | Verfahren zur Herstellung blauer Mikrokapseln |
RS20050177A (en) * | 2002-08-26 | 2007-06-04 | Pfizer Products Inc., | Vaccine for respiratory and reproductive system infections in cattle |
WO2004067031A1 (en) * | 2003-01-29 | 2004-08-12 | Pfizer Products Inc. | Canine vaccines against bordetella bronchiseptica |
PL1613346T3 (pl) * | 2003-04-04 | 2013-03-29 | Zoetis Services Llc | Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek |
SI1742659T1 (sl) * | 2004-04-05 | 2013-07-31 | Zoetis P Llc | Mikrofluidizirane emulzije olja v vodi in sestavki cepiv |
-
2005
- 2005-03-24 SI SI200531727T patent/SI1742659T1/sl unknown
- 2005-03-24 UA UAA200610518A patent/UA89631C2/ru unknown
- 2005-03-24 KR KR1020097009238A patent/KR20090051129A/ko not_active Application Discontinuation
- 2005-03-24 KR KR1020117022798A patent/KR20110132416A/ko not_active Application Discontinuation
- 2005-03-24 PT PT57182925T patent/PT1742659E/pt unknown
- 2005-03-24 AU AU2005230708A patent/AU2005230708B2/en active Active
- 2005-03-24 KR KR1020067020930A patent/KR20070008625A/ko not_active Application Discontinuation
- 2005-03-24 JP JP2007506850A patent/JP5393978B2/ja active Active
- 2005-03-24 CN CN2005800119857A patent/CN1997390B/zh active Active
- 2005-03-24 RU RU2006135121A patent/RU2347586C2/ru active
- 2005-03-24 BR BRPI0509606A patent/BRPI0509606B1/pt active IP Right Grant
- 2005-03-24 PL PL05718292T patent/PL1742659T3/pl unknown
- 2005-03-24 WO PCT/IB2005/000804 patent/WO2005097181A1/en active Application Filing
- 2005-03-24 EP EP20050718292 patent/EP1742659B1/en active Active
- 2005-03-24 KR KR1020087018863A patent/KR20080073376A/ko not_active Application Discontinuation
- 2005-03-24 KR KR1020087031330A patent/KR101143060B1/ko active IP Right Grant
- 2005-03-24 ES ES05718292T patent/ES2409782T3/es active Active
- 2005-03-24 DK DK05718292T patent/DK1742659T3/da active
- 2005-03-24 EP EP20100178441 patent/EP2269644A3/en not_active Withdrawn
- 2005-03-24 CA CA2561914A patent/CA2561914C/en active Active
- 2005-03-24 NZ NZ550152A patent/NZ550152A/en unknown
- 2005-04-01 US US11/096,831 patent/US7122191B2/en active Active
- 2005-04-01 TW TW94110524A patent/TWI301067B/zh active
- 2005-04-04 AR ARP050101316 patent/AR048822A1/es not_active Application Discontinuation
- 2005-04-04 UY UY28840A patent/UY28840A1/es not_active Application Discontinuation
-
2006
- 2006-10-02 ZA ZA200608200A patent/ZA200608200B/xx unknown
- 2006-11-02 NO NO20065039A patent/NO341034B1/no unknown
-
2007
- 2007-12-20 HK HK07113918A patent/HK1108830A1/xx unknown
-
2011
- 2011-04-13 JP JP2011089018A patent/JP2011168605A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509606A (pt) | emulsões de óleo-em-água microfluidizadas e composições para vacinas | |
BRPI0408635A (pt) | emulsões de óleo em água microfluidizadas e composições de vacinas | |
AR054251A1 (es) | Vacuna de toxoide de c. perfringens alfa | |
MA29714B1 (fr) | Vaccin | |
DOP2013000029A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
MX2007003402A (es) | Composicion inmunogena para su uso en vacunacion contra estafilococos. | |
WO2008112344A3 (en) | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins | |
PT2364724E (pt) | Composição de vacina compreendendo um adjuvante de saponina | |
AR014182A1 (es) | Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones | |
UY31101A1 (es) | Composición antigénica liofilizada | |
DK1112747T3 (da) | Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller | |
DK1350839T3 (da) | Identificering af de virulensassocierede regioner RD1 og RD5, hvilket muliggør udvikling af forbedrede vacciner af M. bovis BCG og M. microti | |
ATE529123T1 (de) | Synthetische glykolipopeptide als impfstoffe | |
DE60143755D1 (de) | Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen | |
BR0315980A (pt) | Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos | |
GB2444676A (en) | Adjuvanted vaccine | |
ATE401344T1 (de) | T-zellen-epitope in erythropoietin | |
ATE310008T1 (de) | Immunologische adjuvans verbindungen | |
UY32930A (es) | Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas | |
WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
WO2007028985A3 (en) | Adjuvanted vaccine | |
BR0207447A (pt) | Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina | |
BR0308180A (pt) | protéinas de superfìcie de leptospira | |
TH72570B (th) | อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน | |
DE60036705D1 (de) | Adjuvanskombinationen zur immunisierung und vakzine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: PAH USA 15 LLC (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: ZOETIS P LLC (US) |
|
B25A | Requested transfer of rights approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
B25G | Requested change of headquarter approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |